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ABSTRACT 
 
The -amyloid protein, component of the senile plaques found in Alzheimer 
brains is proteolytically derived from the -amyloid precursor protein (APP), a 
larger membrane-associated protein that is expressed in both neural and 
nonneural cells. Overexpression of APP might be one of the mechanisms that 
more directly contributes to the development of Alzheimer disease. APP gene 
expression is regulated by a number of cellular mediators including nerve growth 
factor (NGF) and other ligands of tyrosine kinase receptors. We have previously 
described that NGF increases APP mRNA levels In PC12 cells. However, the 
molecular mechanisms and the precise signaling patways that mediate its 
regulation are not yet well understood. In the present study we present evidence 
that NGF, and to a lesser extent fibroblast growth factor (FGF) and epidermal 
growth factor (EGF), stimulate APP promoter activity in PC12 cells. This 
induction is mediated by DNA sequences located between the nucleotides -307 
and -15, and involves activation of the Ras-MAP kinase signaling pathway. In 
contrast, we have also found that NGF-induced secretion of soluble fragments of 
APP into the culture medium is mediated by a Ras independent mechanism. 
 
 
 
 
 
 
 
 
Running title: NGF regulate synthesis and secretion of APP by different 
mechanisms. 
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INTRODUCTION 
 
 One of the characteristic features of Alzheimer's disease is the presence 
of senile plaques in which the -amyloid protein, a 40-42 aminoacids peptide, is 
the major component. This 4 kDa peptide is derived by proteolytic cleavage from 
a set of alternatively spliced -amyloid precursor proteins (APP), which are 
encoded by a single gene located on chromosome 21 (Selkoe, 1994). The APP 
gene is ubiquitously expressed in mammalian tissues, and gives rise to three 
major APP messenger RNAs that encode for the isoforms APP695, APP751 and 
APP770. The precursor protein APP plays a central role in the Alzheimer's 
disease, and significant alterations of APP expression might contribute to its 
development (Zhong et al., 1994). The appearance of an Alzheimer-like 
pathology in Down's syndrome, probably due to the trisomy 21-associated 
duplication of the APP gene (Neve et al., 1988), the degeneration of neurons 
overexpressing APP (Yoshikawa et al., 1992) or the appearance of -amyloid-
immunoreactive deposits in transgenic mice carrying the human APP cDNA 
(Games et al., 1995; Quon et al., 1991), strongly suggest a positive correlation 
between the overexpression of APP and the formation of amyloid deposits.  
 Overexpression of the APP gene might result in an aberrant processing of 
the amyloid precursor, which leads to a higher concentration of amyloidogenic 
fragments, and is associated with the formation of -amyloid deposits in the 
brain (Fukuchi et al., 1992). APP gene expression is regulated in different cell 
types by a variety of stimuli, including phorbol esters (Trejo et al., 1994; Yoshikai 
et al., 1990), thyroid hormones (Belandia et al., 1998; Latasa et al., 1998), or 
retinoic acid (Konig et al., 1990). In addition, and since NGF is considered to be 
of benefit in Alzheimer´s and other neurodegenerative diseases, it results of 
special interest the effects induced by NGF and other neurotrophins on APP. 
Nerve growth factor (NGF), the best characterized neurotrophic factor, has been 
found to increase APP mRNA in SH-SY5Y human neuroblastoma cells (Konig et 
al., 1990), in mouse brain primary cultures (Ohyagi and Tabira, 1993) and in 
developing hamster brain (Mobley et al., 1988). In PC12 cells, a rat 
pheochromocytoma cell line which constitutively expresses APP, NGF has been 
reported to influence transcript levels (Cosgaya et al., 1996), splicing of APP 
mRNA isoforms (Fukuyama et al., 1993; Smith et al., 1991), localization 
(Fukuyama et al., 1993), catabolism and secretory processing of APP (Refolo et 
al., 1989; Rossner et al., 1998). Moreover, it has been also suggested that APP 
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might act to mediate the effects induced by NGF on neurite outgrowth (Milward 
et al., 1992). However, up to date the precise mechanisms involved in this 
regulation remain largely unclear.  
 The trophic effects of NGF are mediated by the specific tyrosine kinase 
receptor TrkA, and also by the low-affinity neurotrophin receptor p75NTR 
(Barbacid, 1994; Segal and Greenberg, 1996). NGF binds to the receptor, and 
activates various intracellular signaling pathways that mediate the 
phosphorylation of specific transcription factors, the activation of target genes, 
and finally the biological responses induced by the neurotrophin. Accumulating 
evidence indicates that binding of NGF to its receptors, p75NTR and TrkA, 
mediates the responses of the neurotrophin on APP mRNA expression, splicing, 
and protein secretion in PC12 cells (Rossner et al., 1998). In addition, TrkA 
receptor gene expression is decreased in nucleus basalis (Higgins and Mufson, 
1989), and parietal cortex (Hock et al., 1998) of patients with Alzheimer's 
disease, suggesting that this receptor could play a role in the neurodegenerative 
process associated with this pathology. We have previously reported that in 
PC12 cells NGF, as well as epidermal (EGF) and basic fibroblast (bFGF) growth 
factors, increase APP mRNA levels by a mechanism that very likely involves 
activation of ras (Cosgaya et al., 1996), and is probably mediated by specific 
sequences of the APP promoter (Lahiri and Nall, 1995; Lahiri et al., 1999). 
However, the exact mechanisms, and the precise signaling pathways that 
mediate these effects of NGF remain elusive. 
 In this work we have examined the role of the ras oncogene in the 
response induced by NGF on APP in PC12 cells, and also in two different 
subclones of PC12 stably transfected with a dominant negative mutant of the ras 
oncogene (M-M17-26), or with an activated ras oncogene under control of the 
MMTV promoter (UR61). We have determined the promoter activity induced by 
NGF or dexamethasone in those cell lines, and partially analyzed the sequences 
of DNA that mediate the response of the APP promoter to NGF. We have also 
examined whether the mitogen-activated protein kinase cascade is involved in 
this response by using several dominant negative mutants, and finally analyzed 
the specific pattern of intracellular and secreted isoforms of APP induced by 
NGF in these cells. NGF induces the APP promoter activity, and according to our 
results this activation is mediated by Ras throughout the MAP kinase signaling 
pathway. NGF-induced activation of the promoter and the specific increase of 
the intracellular content of APP. In contrast, the release of APP isoforms to the 
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culture medium appeared to be quite Ras-independent. On the other hand, the 
response to NGF was significantly reduced in a small fragment (-15/+102) of the 
promoter that, however, maintains a residual response likely involving direct 
effects of NGF on different components of the basal transcriptional machinery. 
 
MATERIALS AND METHODS 
 
 Cell cultures - PC12 cells were cultured in RPMI medium containing 10% 
donor horse serum (Quality Biological Inc.) and 5% fetal calf serum (GIBCO) in 
collagen-treated plates. The subclones of PC12 cells, UR61 and M-M17-26 cells, 
were grown in a similar medium containing 10% horse serum - 5% fetal calf 
serum. UR61 cells were derived from PC12 cells following transfection with a 
plasmid containing the transformant mouse N-ras oncogene under the 
transcriptional control of the dexamethasone-inducible mouse mammary tumor 
virus promoter (Guerrero et al., 1988). The PC12 subline M-M17-26, was 
obtained by Szeberényi et al. (Szeberenyi et al., 1990) after transfection with the 
dominant negative mutant Ha-ras (Asn-17) gene transcribed from the promoter 
of the mouse methallothionein-1 gene. This subclone constitutively express high 
levels of mutant Ras (Val-12) protein which could not be further induced by zinc. 
In our culture conditions both subclones, as well as parental PC12 cells, exhibit 
more than 95% viability as determined by trypan blue exclusion. In addition, 
proliferative ability of M-M71-26 cells is not affected by constitutive expression of 
RasAsn17 (Szeberényi et al., 1990). In UR-61 cells, RasVal12 induces 
differentiation; however, differentiation is not accompanied by a decrease in the 
protein content per culture. The same occurs in parental PC12 cells treated with 
NGF, whereas proliferative ability of M-M17-26 cells is not significantly affected 
by the neurotrophin. 
 The PC12 subclones were incubated with the different factors at the 
concentrations and for the times indicated in the figures. NGF and 
dexamethasone were obtained from Sigma, and bFGF and EGF were obtained 
from Austral Biologicals.  
 
 Plasmids - The chloramphenicol acetyl transferase (CAT) reporter plasmid 
containing the -1099/+105 fragment of the human APP gene has been 
previously described (Belandia et al., 1998). Progressive 5' deletions to -487, -
307, -15 +55 and +75 bp were prepared by polymerase chain reaction from the 
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original -1099/+105 bp fragment, kindly provided by Dr. Lahiri's laboratory (Lahiri 
and Robakis, 1991), and subcloned into the BamH1 site of pBL-CAT8, a plasmid 
which lacks the AP-1 binding site present in the pUC backbone. Expression 
vectors for the dominant negative mutants of Ras, Raf and MAPK have been 
previously described. These vectors contain the inhibitory Ha-rasAsn17 mutant 
(Feig and Cooper, 1988), a dominant negative raf (Raf-C4) (Bruder et al., 1992), 
or the Chinese hamster p44MAPK mutated in the kinase domain (Meloche et al., 
1992). 
 
 DNA transfection and determination of CAT activity -  The PC12 cells were 
transfected in Dulbecco´s modified Eagle´s medium (DMEM) containing 10% 
fetal calf serum. The RPMI growing culture medium was replaced by DMEM 
four-six hours before transfection, and cells transfected by the calcium 
phosphate coprecipitation method with 1g of reporter plasmids and carrier DNA. 
One hundred nanograms of a luciferase reference vector was simultaneously 
used as an internal control of the transfection efficiency. In cotransfection 
experiments, 1g of reporter plasmid and 10 g of the corresponding dominant 
negative expression vector were used. After 16h of incubation in the presence of 
calcium phosphate, the medium was discarded and washed with 5 ml of 
phosphate-buffered saline. A new RPMI medium containing 0,5% serum was 
added and the cells were then incubated for an additional period of 48 hours in 
the presence or absence of NGF (50 ng/ml). Each treatment was performed in 
duplicate cultures that normally showed less than 5-15% variation in CAT activity 
which was determined by incubation of [14C]-chloramphenicol with the same 
amount of cell lysate protein. After autoradiography, the non-acetylated and 
acetylated [14C]-chloramphenicol were quantified. Each experiment was 
repeated at least 2-3 times with similar relative differences in regulated 
expression. All data are expressed as the mean ± standard deviation.  
 
 Western blot analysis. - Cellular proteins were extracted by lysis with a 
buffer (150 mM NaCl, 50 mM Tris pH8, 2 mM EDTA, 1% Triton, 0.1% SDS) 
containing the protease inhibitors PMSF (1 mM) and leupeptin (10 g/ml). The 
protein content of cells was determined by using the BCA assay (Pierce. Illinois), 
according to the manufacturer's instructions. Identical amounts, 40 g, of cell 
extracts were then electrophoresed in a 8% SDS-polyacrylamide gel and 
transferred to an immobilon polyvinylidine difluoride membrane. Non specific 
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binding was blocked with 5% nonfat dried milk in TBS-T (Tris buffered saline, 
0.1% Tween 20) for 2-3 h at room temperature and the cellular APP detected 
with a 1/1,500 dilution of the rabbit polyclonal antibody 369A, raised against the 
carboxi-terminal domain of human APP. After 1 hour incubation at room 
temperature the membrane was washed and incubated with a second 
biotinylated anti-rabbit antibody (1/2,000) for an additional hour, washed again 
and finally incubated for 1 hour with 1/2,000 peroxidase-conjugated 
streptavidine. All incubations took place at room temperature, and detection by 
enhanced chemiluminiscence (ECL, Amersham International plc. England) was 
carried out according to manufacturer's indications. 
 Secreted full-length APP isoforms were detected by the same method 
from 50 l (1:100 from total) of conditioned medium using the monoclonal 
antibody 22C11 at a final concentration of 10 g/ml. The apparent molecular 
mass (kDa) of the detected bands was always determined by using a wide range 
protein standard (Mark 12 from Novex.-S. Diego. CA).  
 
RESULTS 
 
Induction of APP promoter activity by NGF and other neurotrophins. 
 
 We have previously reported that NGF, as well as EGF or bFGF, 
effectively increases APP-mRNA levels in PC12 cells by a mechanism that 
requires activation of Ras (Cosgaya et al., 1996). To examine whether the 
specific changes induced by these growth factors on the APP mRNA are induced 
at transcriptional levels, we analyzed the effect of NGF, EGF and bFGF on the 
APP promoter activity. As shown in figure 1A, treatment with 50 ng/mlNGF for 48 
hours, induced by almost 4-fold the CAT activity in PC12 cells transiently 
transfected with a chimeric plasmid containing the APP promoter linked to the 
CAT reporter gene. EGF and bFGF also stimulated APP promoter activity 
although their effect was weaker than that found with NGF. Since the ras 
oncogene is involved in different actions of growth factors ligands of tyrosine 
kinase receptors in PC12 cells, we examined the effect of activated Ras on APP 
promoter activity in the PC12 subline UR61 which contains a transfected N-Ras 
oncogene (Rasval12) under control of the glucocorticoid-incucible MMTV 
promoter. Figure 1B shows that promoter activity was significantly induced in 
UR61 cells treated for 48 hours with 100 nM dexamethasone. Since, as also 
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shown in figure 1A, dexamethasone treatment of PC12 cells did not increase 
promoter activity, these results indicate that activated ras is responsible for 
promoter stimulation by the glucocorticoid in UR61 cells. The induction of of APP 
promoter activity by dexamethasone in UR61 was comparable to that produced 
by NGF in the parental PC12 cells. In contrast, NGF caused a weaker increase 
in UR61 cells, in which the neurotrophin does not elicit neurite outgrouth 
(Cosgaya et al., 1997; Guerrero et al., 1988). 
 To determine whether endogenous Ras is required for growth factor 
stimulation of the APP promoter in PC12 cells, we examined the ability of NGF, 
EGF and bFGF to increase APP promoter activity in the PC12 subclone M-M17-
26 which as indicated above constitutively expresses the dominant inhibitory 
RasAsn17 mutant. As illustrated in figure 1C, neither growth factor was able to 
stimulate APP promoter activity in the presence of the dominant negative ras 
mutant, showing the requirement of functional Ras for this response. 
 
 Characterization of the signaling pathway that mediates the effects of NGF 
on the APP promoter. 
 
 The results obtained in M-M17-26 cells transfected in a stable manner with 
the dominant inhibitory ras mutant were confirmed in parental PC12 cells 
transiently transfected with RasAsn17. Figure 2 shows that transfection with this 
mutant totally abolished the response to NGF in PC12 cells. Since Raf can act 
downstream of Ras in growth factor signal transduction, the influence of transient 
transfection with an expression vector for a dominant negative form of Raf was 
also analyzed. As shown in figure 2, the mutant Raf had an effect identical to 
that caused by RasAsn17, blocking the response of the APP promoter to the 
neurotrophin in PC12 cells. The same was found with a MAP kinase mutant, 
which also reduced very significantly the promoter response to NGF. In addition, 
transfection of these mutants decreased basal CAT levels (data not shown), thus 
suggesting that even in the absence of NGF exist a certain activation of the 
Ras/MAPK pathway that contributes to basal APP promoter activity. 
 
Identification of DNA regions mediating the regulation of APP 
transcriptional activity. 
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 To map the DNA sequences of the APP gene that mediate the NGF-
induced response, progressively deleted fragments of the promoter (-1099, -487, 
-307 and -15) were linked to the CAT reporter gene and transfected into PC12 
cells. As illustrated in figure 3, not only the basal activity, but also the response 
to NGF was affected along the different fragments of promoter studied. Deletion 
from nucleotides -1099 to -487 increased basal promoter activity without 
affecting significantly the response to NGF. Deletion to nucleotide -307 caused a 
decrease of CAT levels which were similar to those found with the fragment 
extending to nucleotide -1099. In addition, induction with NGF was similar, 
indicating that sequences between nucleotides -307 and -1099 do not 
significantly contribute to the response of the APP promoter to NGF. However, 
further deletion of sequences between -307 and -15 caused not only a strong 
decrease of basal promoter activity, but also a marked reduction of the response 
to NGF, since only a residual response to the neurotrophin was found in PC12 
cells transfected with the plasmid containing the -15 t0 +102 fragment. 
 
Effects of NGF on the cell-associated proteins and the accumulation of 
secreted forms into the culture medium. 
 
 After 48 hours of incubation in the presence or in the absence of NGF 
(PC12 and M-M17-26 cells), or dexamethasone (UR61 cells), the content of APP 
was analyzed in cells and culture medium by Western blot using the antibodies 
369A and 22C11, respectively. The analysis of the intracellular APP isoforms is 
illustrated in figure 4A. Based on previous descriptions, the immunoreactive 
bands detected by Western blot analysis in PC12 cells contain at least six 
protein species corresponding to immature and mature forms of APP (APP695, 
APP751 and APP770) (Buxbaum et al., 1990; Weidemann et al., 1989). 
Incubation of PC12 cells with NGF (50 ng/ml) for 48 hours, does not affect the 
general pattern of intracellular proteins (data not shown), but leads to a 
generalized increase of the intracellular APP content, that is not observed in the 
M-M17-26 cell line which constitutively expresses the dominant negative Ras 
mutant. In contrast, incubation of UR61 cells with 100 nM dexamethasone, which 
induces the expression of the stably transfected Ras oncogene, leads to a 
similar increase in the intracellular content of APP. In addition, dexamethasone 
did not affect the intracellular content of APP in the native PC12 cells or in M-
M17-26 cells (data not shown). Figure 4B shows the effects of NGF and 
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dexamethasone on the levels of APP soluble isoforms accumulated into the 
culture medium. As expected, NGF treatment leads to an increased sAPP 
content in the PC12 conditioned medium. However, and in contrast to that 
observed with the intracellular APP content, the amount of secreted isoforms 
was not modified by dexamethasone in UR61 cells. Furthermore, the amount of 
sAPP accumulated into the culture medium was increased in the NGF-treated M-
M17-26 cells.  
 
DISCUSSION 
 
 It has been extensively documented that NGF can modulate the 
postranscriptional processing and secretion of APP in PC12 cells (Refolo et al., 
1989; Rossner et al., 1998; Rossner et al., 1999). In addition, we have previously 
demonstrated that NGF, as well as the growth factors bFGF and EGF, increases 
APP-mRNA levels through a Ras-dependent mechanism (Cosgaya et al., 1996).  
 In this study we have examined the effects of NGF on APP expression in 
three variants of PC12 cells, the parental cell line and two different subclones, 
which represent a good model to investigate the role of Ras in NGF-induced 
effects in PC12 cells. UR61 cells express oncogenic N-ras and M-M17-26 cells 
contain a dominant inhibitory mutant of ras.  Transient transfection studies 
demonstrate that NGF and to a lesser extent bFGF and EGF stimulate APP 
promoter activity in PC12 cells. It has been reported that NGF can stimulate APP 
promoter activity when these cells are treated with the growth factor for a 
duration of four days prior to and four days after transfection with a plasmid 
containing the APP promoter (Lahiri and Nall 1995). We demonstrate here that 
48 hours of incubation with NGF after transfection are sufficient to activate the 
APP promoter. These results demonstrate that NGF increases APP gene 
expression at transcriptional level. 
 Activation of the protein tyrosine kinase receptors initiates a cascade of 
intracellular signalling events leading to regulation of specific genes and finally to 
regulation of a  wide variety of cellular responses. Numerous proteins and 
several second messengers, among them the Ras-MAP kinase cascade, have 
been implicated in the signalling pathway that follows binding of neurotrophins to 
their Trk receptors. Evidence that activation of endogenous Ras mediates the 
effects of NGF on APP promoter activity comes from the experiments with the 
PC12 subclone M-M17-26 which constitutively expresses the dominant inhibitory 
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mutant of ras Asn-17. This mutant has a reduced affinity for GTP and inhibition 
of endogenous Ras function by this mutant has been suggested to occur through 
competition with normal Ras for regulatory proteins which promote nucleotide 
exchange (Feig and Cooper, 1988). Szerebényi et al., (Szeberenyi et al., 1990), 
have shown that the mutant blocks the neurite outgrowth induced by NGF or 
FGF, as well as the induction of different genes. Our present results demonstrate 
that expression of the Asn-17 mutant also blocks the stimulation of APP 
promoter activity induced by NGF in PC12 cells, thus showing the requirement of 
functional Ras for this response. The results obtained in dexamethasone-
induced UR61 cells support this hypothesis further. In this subclone of PC12 
cells the transfected ras proto-oncogene is under control of a dexamethasone 
inducible MMTV promoter. Since dexamethasone does not affect the expression 
of APP in PC12 cells, it can be assumed that Ras is the signal transduction 
pathway used by dexamethasone to increase the intracellular content of APP in 
UR61 cells. Moreover, the results obtained with dominant negative mutants of 
Ras, Raf and MAP kinase, strongly suggest that NGF-induced stimulation of the 
APP promoter activity not only requires activation of Ras, but also the complete 
activation of the Ras-MAP kinase signaling pathway. 
 Many transcription factors which constitute final targets of specific 
transduction pathways (Hunter et al., 1992) bind to specific response elements in 
the regulated genes, and mediate the effects induced by neurotrophins. The 
APP promoter has the typical structure of a housekeeping gene, lacking the 
TATA and CAAT elements. Its sequence is extremely well conserved between 
rat, mouse and human (Chernak, 1993), and contains multiple positive and 
negative regulatory elements and consensus sequences for the binding of 
several transcription factors (La Fauci et al., 1989; Salbaum et al., 1988; 
Quertfurth et al., 1999; Wright et al., 1999; Vostrov et al., 1997). In agreement 
with previous descriptions (Lahiri et al., 2000), we found that progressive 
deletions of promoter sequences led to significant variations of the basal 
promoter activity. This activity was maximal in the construct containing the -487 
fragment of the APP promoter, suggesting the presence of a silencer element 
between this position and the nucleotide -1099, and it was further decreased in 
succesive deletions to nucleotides -307 and -15. Deletion to nucleotide -307 
caused a significant decrease of basal activity, which could be secondary to the 
loss of the "5'-GC element/AP1 site" tandem described in the -383/-358 region of 
the promoter (Quertfurth et al., 1999). Further deletion of sequences to 
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nucleotide -15 caused an additional reduction which very like represents the loss 
of previously described response elements which are essential to maintain the 
basal promoter activity (La Fauci et al., 1989; Salbaum et al., 1988; Quertfurth et 
al., 1999; Vostrov et al., 1997).  
 The response to NGF was maintained in the plasmid which contains the 
first 307 bp of the 5' upstream sequence, but it was significantly reduced in the 
next deletion plasmid extending to nucleotide -15. These results indicate that 
stimulation of the APP promoter activity by NGF is mainly mediated through 
sequences located between nucleotides -307 and -15. In addition the smallest 
promoter fragment used (-15/+102) retains a residual response that probably 
involves direct effects of NGF on different components of the basal 
transcriptional machinery, or alternatively the existence of regulatory sequences 
located downstream of the main transcriptional initiation site. 
 Our results strongly suggest that transcriptional activation of APP gene 
expression is responsible for the NGF-induced increase in APP transcripts 
previously described by us in PC12 cells (Cosgaya et al., 1996). We have 
reported that NGF increases APP mRNA levels in PC12 cells. Furthermore, 
expression of activated ras  in UR61 cells also leads to a significant increase in 
APP transcripts, whereas the expression of a dominant negative mutant of ras 
blocked the induction of APP gene expression by NGF in the M-M17-26 cell line. 
Stimulation of transcription should lead also to an increase in the cellular content 
of APP proteins. This was indeed observed in PC12 cells, where NGF treatment 
resulted in a significant increase in the intracellular levels of the different APP 
isoforms. Moreover, our results indicate that this effect was also largely 
dependent of Ras. As also occurred with promoter activity (Cosgaya et al., 
1996), the NGF-induced increase of cellular APP observed in PC12 cells was not 
reproduced in the M-M17-26 subline, which expresses the inhibitory mutant of 
Ras, and was mimicked by dexamethasone-induced expression of Ras in UR61 
cells. According to our results NGF appears to induce a generalized increase of 
the different APP species detected. However, and since a complete definition of 
bands has not been possible, we cannot exclude that, as previously described 
(Fukuyama et al., 1993), NGF only affected the synthesis of APP695, thus 
increasing specifically the levels of both the immature and mature forms of 
APP695 in PC12 cells.  
 In addition, it has been also reported that NGF, as well as other 
neurotrophins, regulate the secretion of sAPP in PC12 cells (Desdouits-Magnen 
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et al., 1998; Fukuyama et al., 1993; Refolo et al., 1989). In agreement with those 
descriptions we have found that NGF increases the amount of sAPP 
accumulated into the cultured medium in the parental PC12 cells. In contrast, 
expression of activated Ras in the UR61 subline was unable to increase the 
extracellular sAPP content. In addition, the increased release of sAPP induced 
by NGF in PC12 cells was not completely abolished in the M-M17-26 cells which 
express a dominant negative mutant of Ras. Therefore, and contrarily to those 
effects induced by NGF on promoter activity, levels of mRNA, and cellular 
content of APP, the regulation of APP secretion by NGF in PC12 cells appears 
to be mainly mediated by a Ras-independent mechanism.  
 These results are in apparent contradiction with the description that 
activation of the MAP kinase cascade in PC12 results in the rapid secretion of 
sAPP isoforms. Nevertheless, it has been also reported that although activation 
of MAP kinase promotes APP secretion, the inhibition of this kinase is not 
sufficient to reduce APP secretion (Rossner et al., 1999). Taken together, these 
results are compatible with the existence of a Ras-independent mechanism 
responsible for APP secretion in response to NGF in PC12 cells. A number of 
possible mechanisms could explain the specific MAP kinase-dependent / Ras-
independent regulation of APP secretion by NGF. Other TrkA-interacting 
proteins, such as PLC- or PI 3-Kinase (Greene and Kaplan, 1995), or docking 
proteins such as FRS2, that are phosphorylated in response to NGF stimulation 
(Hadari et al., 1998; Kouhara et al., 1997) could be involved in the observed 
effect. In addition, activation of protein kinase C (PKC) downstream of PLC- 
could contribute to Ras-independent activation of MAP kinase through PKC 
phosphorylation of Raf (Sozeri et al., 1992).  
 Our results demostrate that NGF activates transcription of the APP gene, 
thus increasing expression of APP.  If this also occurs in humans in vivo, the use 
of NGF, proposed as a paliative treatment in Alzheimer, could rather result in a 
risk factor for the disease. However, the neurotrophins can also increase the 
release of neurotrophic sAPP fragments, which very likely should be 
accompanied by a reduced generation and release of the -amyloid peptide. If 
this is the case NGF could indeed be useful to define new therapeutic strategies 
for the disease. Therefore, it will be of interest to analyze the effect of NGF on 
APP gene expression and on the secretion of neurotrophic sAPP in humans. 
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LEGEND TO THE FIGURES 
 
Fig. 1. 
Regulation of APP promoter activity by NGF and other neurotrophins in PC12 
cells.  
Promoter activity was determined in three different subclones of PC12 cells, the 
native cell line (left panel), the M-M17-26 cell line which expresses a dominant 
negative ras mutant (rigth panel), and UR61 cells which express the N-ras (val-
12) oncogene in response to dexamethasone (middle panel). The cells were 
transfected with a CAT reporter gene containing the -1099/+105 fragment of the 
APP promoter, and CAT activity was measured after a 48 h period of incubation 
in the presence or absence of 100 nM dexamethasone (Dex), 50 ng/ml NGF, 17 
ng/ml bFGF or60 ng/ml EGF. CAT activity was normalized for total protein, and 
results are expressed as fold induction over the levels obtained in the 
corresponding control untreated cells. Data are the mean ± SD from three 
independent experiments. 
 
Fig. 2. 
Stimulation of APP promoter activity by NGF is mediated by the MAP kinase 
signaling pathway in PC12 cells.  
The CAT plasmid containing the -1099/+105 fragment of the APP promoter was 
transfected alone or in combination with dominant negative forms (dn) of Ras, 
Raf and MAPK. CAT activity was determined in untreated cells and in cells 
treated with 50 ng/ml NGF for 48 h. CAT activity is expressed in each case as 
fold induction above the control values found in NGF-untreated cells, and 
represent mean ± SD values of four determinations (duplicates from two 
independent experiments).   
 
Fig. 3. 
Analysis of DNA regions that mediate the effect of NGF on the APP promoter. 
PC12 cells were transiently transfected with pBL-CAT plasmids containing 
progressive deletions of the APP promoter and CAT activity was determined in 
cell extracts after a 48 h incubation in the absence or presence of NGF. Data are 
expressed relative to CAT activity obtained with the construct containing the -
1099 to + 105 bp fragment and are the mean ± SD from two separate 
experiments performed with duplicates. 
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Fig. 4. 
Western blot analysis of cellular and secreted APP isoforms. 
After 48 h of incubation in the absence or presence of NGF (PC12 and M-M17-
26 cells), or dexamethasone (UR61 cells), the intracellular and secreted isoforms 
of APP were analyzed by western blot with the antibodies 369 A (A) and 22C11 
(B), respectively. The figure include the blots obtained in a representative 
experiment. The apparent size (kilodaltons) of the protein bands is indicated at 
the rigth by arrows. The relative changes induced by the different treatments are 
indicated by a number, at the bottom, that represents the mean ± SD obtained 
from three independent experiments 
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